Nanosphere announced today that it has completed a $10 million public offering.
 

The Northbrook, Illinois-based molecular diagnostics firm priced the offering at $.47 per share. Each share was coupled with a five-year warrant to purchase one share of common stock at an exercise price of $.70 per share.
 

The firm said in a statement that it plans to use the funds for working capital and general corporate purposes.
 

Rodman & Renshaw, a unit of H.C. Wainwright, acted as the sole book runner for the offering.  Joseph Gunnar & Co. acted as a co-manager and LifeSci Capital acted as a financial advisor in connection with the offering.
 

Nanosphere, which makes the Verigene infectious disease diagnostics platform,amended its prospectus for the offering earlier this month.